Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
批准号:
8725332
负责人:
Xuebin Qin
金额:
$22.37万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-02-01 至 2018-01-31
关键词:
AdjuvantAntibodiesAntineoplastic AgentsB lymphoid malignancyB-LymphocytesBacteriophagesBlood CirculationBody WeightCell LineCell surfaceCellsChronic Lymphocytic LeukemiaClinical TrialsComplementComplement Membrane Attack ComplexComplement-Dependent CytotoxicityDetectionDoseErythrocytesHalf-LifeHemolysisHumanImmune responseIn VitroInhibitory Concentration 50LeadLibrariesLymphomaMalignant - descriptorMalignant NeoplasmsMediatingMetabolicMusNon-Hodgkin&aposs LymphomaOutcomes ResearchParentsPeptidesPhage DisplayPropertyPublishingRelapseResistanceSeriesSolubilityTestingTherapeuticTherapeutic antibodiesToxic effectTransgenic MiceTreatment EfficacyUp-RegulationWorkbasecancer cellcancer therapycytotoxicitygene synthesisgenetic regulatory proteinimmunogenicimmunogenicityimprovedin vivoinhibitor/antagonistnovel therapeuticsoverexpressionrituximabtherapeutic development
中文摘要
描述(由申请人提供):利妥昔单抗(RTX)和Ofatumumab (OFA)在癌症治疗中的有效性部分依赖于补体依赖性细胞毒性(CDC)的诱导。人CD59 (hCD59)是一种关键的补体调节蛋白,它限制了膜攻击复合物(MAC)的形成,从而抑制了CDC的诱导。hCD59在非霍奇金淋巴瘤(NHL)和慢性淋巴细胞白血病(CLL)等b细胞恶性肿瘤中高表达,hCD59表达上调是这些癌细胞对RTX治疗敏感性的重要决定因素。因此,我们迫切需要开发一种能够消除CD59在癌细胞中的功能的分子,从而促进抗体介导的癌症治疗。然而,针对hCD59的抗体的靶向毒性作用和C8或C9肽的疗效较低限制了它们的治疗目的。最近,我们开发了一种特异性和有效的hCD59抑制剂rILYd4 (114aa),并证明了rILYd4在体外和体内增强CDC,从而使RTX耐药淋巴瘤细胞和原发性CLL对RTX和OFA治疗敏感。通过确定小鼠rILYd4的PK/PD谱,我们发现rILYd4本身不会对表达hcd59的红细胞的体内溶血产生不利的介导作用。我们证明,在rtx耐药细胞中,hCD59表达水平的增加是由于对已有克隆的选择,而不是hCD59的从头诱导。我们还证明了OFA或RTX对抗RTX的b细胞恶性细胞系和CLL细胞介导的CDC效应的敏感性与细胞表面CD59水平呈负相关。综上所述,我们的研究结果证明了rILYd4作为RTX和OFA治疗RTX耐药NHL和CLL的治疗辅助剂的合理性。基于这些结果,我们建议对rILYd4进行优化,开发低免疫原性或无免疫原性、强效且稳定的rILYd4衍生肽。我们假设优化后的rILYd4将改善亲本rILYd4的理化性质,消除或显著降低免疫原性,增加代谢稳定性和循环半衰期,提高治疗效果,从而导致有效的rILYd4相关治疗,作为抗癌药物如OFA和RTX的辅助治疗,在先前基于抗体的治疗后复发的b细胞恶性肿瘤。我们建议:1)通过噬菌体展示和合成的方法鉴定rILYd4中抗hCD59活性的序列,并利用它们开发一个小的、有效的、非免疫原性的rILYd4衍生肽(衍生物)(目的1)和2),研究其在人HLA转基因小鼠中的免疫应答,并表征其在人源化hCD59转基因小鼠中的PK/PD、功效和毒性谱。(目标2)。这项研究的成功结果将产生一种新的治疗性rilyd4衍生药物,用于临床试验,将测试其作为RTX或ofa为基础的b细胞恶性肿瘤治疗的辅助剂的功效,并提供急需的手段来克服破坏性的RTX或ofa抗性b细胞恶性肿瘤。
英文摘要
DESCRIPTION (provided by applicant): Rituximab (RTX) and Ofatumumab (OFA) efficacies in cancer therapy depend in part on the induction of complement-dependent cytotoxicity (CDC). Human CD59 (hCD59) is a key complement regulatory protein that restricts the formation of membrane attack complex (MAC), thereby inhibiting induction of CDC. hCD59 is highly expressed in B-cell malignancies such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) and up-regulation of hCD59 expression is an important determinant of the sensitivity of those cancer cells to RTX treatment. Therefore, it is imperative for us to develop a molecule capable of abrogating CD59 function in cancer cells and thus facilitate antibody- mediated cancer therapy. However, targeted toxicity effect from antibody specific against hCD59 and less efficacy of C8 or C9 peptides limit them for therapeutic purposes. Recently, we developed a specific and potent hCD59 inhibitor, rILYd4 (114aa), and demonstrated that rILYd4 enhances CDC in vitro and in vivo, thereby sensitizing RTX resistant lymphoma cells and primary CLL to RTX and OFA treatment. By defining PK/PD profiles of rILYd4 in mice, we showed that by itself rILYd4 does not adversely mediate in vivo hemolysis of hCD59-expressing erythrocytes. We demonstrated that increasing expression level of hCD59 in RTX-resistant cells occurs due to selection of pre-existing clones, rather than de novo induction of hCD59. We also demonstrated that the sensitivity to CDC effects mediated by OFA or RTX on RTX-resistant B-cell malignant cell lines and CLL cells negatively correlated with the level of CD59 on the cell surface. Taken together, our results rationalize the use of rILYd4 as a therapeutic adjuvant for RTX and OFA treatment of RTX-resistant NHL and CLL. Based on these results, we propose to optimize rILYd4 and develop less or non immunogenic, potent and stable rILYd4-derived peptide. We hypothesize that the optimized rILYd4 will improve the physicochemical properties of parental rILYd4, eliminate or reduce markedly immunogenicity, increase metabolic stability and half life in circulation, and enhance therapeutic efficacy, thereb leading to effective rILYd4-related therapeutics for enhancing as a adjuvant to anti-cancer drugs such as OFA and RTX in B-cell malignancies that have relapsed after prior antibody-based therapies. We propose to 1) to identify the sequences in rILYd4 responsible for its anti-hCD59 activity by phage display and synthetic approaches, and use them to develop a small, potent and non-immunogenic rILYd4-derived peptide (derivative) (Aim 1) and 2) to study its immune responses in human HLA transgenic mice and characterize its PK/PD, efficacy and toxicity profiles in humanized hCD59 transgenic mice. (Aim 2). Successful outcome of this research will generate a novel therapeutic rILYd4-derived agent for clinical trials that will test its efficacy a an adjuvant for RTX- or OFA-based B-cell malignancy therapy and provide the much needed means to overcome the devastating RTX- or OFA-resistant B-cell malignancies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of Complement Activation in Severe COVID-19
-
批准号:10765317
-
项目类别:
-
资助金额:$18.66万
-
财政年份:2023
-
负责人:Xuebin Qin
-
依托单位:
Role of Complement Activation in Severe COVID-19
-
批准号:10512248
-
项目类别:
-
资助金额:$69.08万
-
财政年份:2022
-
负责人:Xuebin Qin
-
依托单位:
Role of Complement Activation in Severe COVID-19
-
批准号:10687821
-
项目类别:
-
资助金额:$67.43万
-
财政年份:2022
-
负责人:Xuebin Qin
-
依托单位:
Renal Macrophage Biology
-
批准号:10610904
-
项目类别:
-
资助金额:$51.09万
-
财政年份:2022
-
负责人:Xuebin Qin
-
依托单位:
Renal Macrophage Biology
-
批准号:10452251
-
项目类别:
-
资助金额:$51.07万
-
财政年份:2022
-
负责人:Xuebin Qin
-
依托单位:
Generation and Characterization of a Novel Cell Subpopulation Ablation Model
-
批准号:9932578
-
项目类别:
-
资助金额:$21.25万
-
财政年份:2019
-
负责人:Xuebin Qin
-
依托单位:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
-
批准号:8791256
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2013
-
负责人:Xuebin Qin
-
依托单位:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
-
批准号:9001317
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2013
-
负责人:Xuebin Qin
-
依托单位:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
-
批准号:8438708
-
项目类别:
-
资助金额:$11.91万
-
财政年份:2013
-
负责人:Xuebin Qin
-
依托单位:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
-
批准号:8607165
-
项目类别:
-
资助金额:$32.48万
-
财政年份:2013
-
负责人:Xuebin Qin
-
依托单位:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
-
批准号:9206145
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2013
-
负责人:Xuebin Qin
-
依托单位:
Abrogating human CD59 activity for antibody-based cancer therapy
-
批准号:8009892
-
项目类别:
-
资助金额:$21.46万
-
财政年份:2010
-
负责人:Xuebin Qin
-
依托单位:
Abrogating human CD59 activity for antibody-based cancer therapy
-
批准号:7786901
-
项目类别:
-
资助金额:$18.43万
-
财政年份:2010
-
负责人:Xuebin Qin
-
依托单位:
Towards a Mouse Model of Complement-Mediated Diseases
-
批准号:7579914
-
项目类别:
-
资助金额:$38.98万
-
财政年份:2005
-
负责人:Xuebin Qin
-
依托单位:
Towards a Mouse Model of Complement-Mediated Diseases
-
批准号:7348386
-
项目类别:
-
资助金额:$38.97万
-
财政年份:2005
-
负责人:Xuebin Qin
-
依托单位:
Towards a Mouse Model of Complement-Mediated Diseases
-
批准号:7016348
-
项目类别:
-
资助金额:$33.1万
-
财政年份:2005
-
负责人:Xuebin Qin
-
依托单位:
Towards a Mouse Model of Complement-Mediated Diseases
-
批准号:6917557
-
项目类别:
-
资助金额:$33.9万
-
财政年份:2005
-
负责人:Xuebin Qin
-
依托单位:
Towards a Mouse Model of Complement-Mediated Diseases
-
批准号:7174295
-
项目类别:
-
资助金额:$32.14万
-
财政年份:2005
-
负责人:Xuebin Qin
-
依托单位:
海外基金